1. Peptide Antibiotics (IV) : ADT-340, ADT-117 or ADT-337

① Target : Gram negative bacteria and MDR bacteria

② Indication : Sepsis

③ In vivo efficacy and toxicity validation

(ADT-340 and ADT-117; ADT-117 by CRO company)

④ Fast tract is possible and available for sale after phase II

clinical trials

1. Peptide Antibiotics for Skin Treatment : ADT-340 or 338

① Target : Gram negative bacteria and MDR bacteria

② Indications: Foot Ulcer and Wound

(Skin treatment by patch loaded with the peptide)

③ In vivo efficacy and in vitro toxicity validation

(ADT-338 and ADT-340)